摘要
目的探讨紫杉醇联合顺铂同步放化疗治疗晚期非小细胞肺癌的临床效果。方法将我院收治的80例晚期非小细胞肺癌患者采用随机数表法分为对照组和观察组,各40例。对照组给予放射治疗,观察组在对照组的基础上,第1、4周给予紫杉醇135 mg/m^2和顺铂70 mg/m^2静脉滴注。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。观察组的胃肠道反应、白细胞减少、血小板减少、骨髓抑制各级发病率高于对照组(P<0.05)。治疗后,两组的CA125、CEA水平均降低,且观察组低于对照组(P<0.05)。随访1、2年,观察组的生存率及无进展生存率均高于对照组(P<0.05)。结论同步放化疗治疗晚期非小细胞肺癌的临床效果显著,但有较严重的不良反应,需谨慎使用。
Objective To investigate the clinical effect of paclitaxel combined with cisplatin concurrent radiotherapy and chemotherapy in the treatment of advanced non-small cell lung cancer. Methods A total of 80 patients with advanced nonsmall cell lung cancer admitted in our hospital were divided into control group and observation group by random number table method, with 40 cases in each group. The control group was given radiotherapy, while the observation group received intravenous infusion of paclitaxel 135 mg/m^2 and cisplatin 70 mg/m^2 at the first and fourth weeks on the basis of the control group. The therapeutic effects of the two groups were compared. Results The total effective rate of treatment in the observation group was higher than that in the control group(P <0.05). The incidences of gastrointestinal reactions,leukopenia, thrombocytopenia and myelosuppression in the observation group were higher than those in the control group(P<0.05). After treatment, the levels of CA125 and CEA in the two groups decreased, and those in the observation group were lower than the control group(P <0.05). During follow-up for 1 and 2 years, the survival rate and progression free survival rate in the observation group were higher than those in the control group(P <0.05). Conclusion Concurrent radiotherapy and chemotherapy is effective in the treatment of advanced non-small cell lung cancer, but it has serious adverse reactions and needs to be used cautiously.
作者
符李达
吴尚
简立智
FU Li-da;WU Shang;JIAN Li-zhi(Xinyang Central Hospital,Xinyang 464000,China)
出处
《临床医学研究与实践》
2020年第2期28-29,共2页
Clinical Research and Practice
关键词
紫杉醇
顺铂
同步放化疗
晚期非小细胞肺癌
paclitaxel
cisplatin
concurrent radiotherapy and chemotherapy
advanced non-small cell lung cancer
